Dosing Guide · Updated November 2026

Mounjaro Dosage Titration: What to Expect From 2.5mg to 15mg

Mounjaro's six dose levels (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg) are designed to be climbed over months. In the SURMOUNT-1 trial, patients on the 15mg dose lost 20.9% of body weight on average at 72 weeks. But the path from your first 2.5mg injection to an effective maintenance dose is not always smooth. Here is what I experienced at each level, what the clinical data shows, and how to decide when to move up or stay put.

I started Mounjaro at 2.5mg in late 2025. As of this writing, I have titrated through multiple dose levels and tracked my weight, side effects, and body composition at each step. This guide is part personal experience, part clinical data, and part practical advice for anyone wondering what each dose increase actually feels like.

If you want general dosing information (pen colors, how to inject, storage), see our Mounjaro dosage guide. This article is specifically about the titration experience: what changes at each level and how to make smart decisions about moving up.

How Mounjaro Titration Works

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist. Unlike Ozempic or Wegovy, which act on the GLP-1 receptor alone, Mounjaro targets two incretin pathways. That dual mechanism is part of why the weight loss numbers in clinical trials were higher than single-agonist medications. If you are moving over from one of those, read switching from Ozempic to Mounjaro first.

Mounjaro is FDA-approved for type 2 diabetes. Zepbound is the same drug approved for weight reduction, so the weight-loss schedule below comes from the Zepbound prescribing information. The Mounjaro prescribing information uses the same 2.5mg start, 2.5mg steps, and 15mg adult maximum.

Start at 2.5mg for 4 weeks (the label says this dose is for starting treatment and is not approved as a maintenance dose)
Increase to 5mg for at least 4 weeks
Increase by 2.5mg steps after at least 4 weeks on the current dose, as needed, up to 15mg

Your provider can adjust this schedule based on how you respond. Some patients stay at lower doses for longer. The label does not allow moving up sooner than 4 weeks. The key word is “as needed,” meaning not everyone needs to reach 15mg. If you want to move up and your prescriber says no, read what to do when your doctor won’t raise your dose. On a compounded vial, the same mg dose can mean a different number of units, so check the tirzepatide units chart against your pharmacy label.

Dose-by-Dose Breakdown: What to Expect

2.5mg: The On-Ramp (Weeks 1 to 4)

The starting dose is intentionally sub-therapeutic. Eli Lilly designed it as a tolerance-building phase to let your body adjust to the medication before hitting effective levels.

What I experienced: Mild appetite suppression that kicked in around day 3 after my first injection. I was not “full” all day, but I noticed I could stop eating midway through a meal without the usual resistance. Portions got smaller without me forcing it. No nausea at this dose.

What the data shows: SURMOUNT-1 did not test 2.5mg as a treatment dose. It was only the first step of a 20-week dose-escalation period. Slow progress in the first month is expected. The 2.5mg dose is doing its job by introducing tirzepatide to your system without overwhelming your GI tract.

Common side effects: Most people tolerate 2.5mg well. Mild nausea affects some patients, usually in the first few days after injection. Constipation is more common than people expect. Fatigue is possible but uncommon.

How long to stay: 4 weeks minimum. The label does not list 2.5mg as a maintenance dose, so it is a stepping stone. Your prescriber may keep you there longer if side effects are a problem.

5mg: Where Treatment Begins (Weeks 5 to 8+)

The 5mg dose is where most patients start to feel the medication working at a meaningful level. In the SURMOUNT-1 trial, patients randomized to the 5mg group lost an average of 15.0% of body weight over 72 weeks.

What I experienced: The jump from 2.5mg to 5mg was noticeable within 48 hours of the first 5mg injection. Appetite suppression was significantly stronger. I went from “I can eat less” to “I genuinely forget to eat lunch.” My first week at 5mg, I lost 3 lbs. Nausea showed up for the first time, mild but persistent for about 5 days, then it faded.

What the data shows: 5mg is considered the first therapeutic dose. Most patients see meaningful weight loss here. In SURMOUNT-1, participants started at an average of 104.8 kg (about 231 lbs), so the 5mg group lost roughly 35 lbs on average over 72 weeks. The Zepbound label lists 5mg as one of three maintenance doses for weight.

Common side effects: Nausea (25% of patients on 5mg in the pooled weight-loss trials in the Zepbound label, versus 8% on placebo), diarrhea (19%), constipation (17%), and vomiting (8%). The SURMOUNT-1 authors reported that GI side effects were mostly mild to moderate and happened mainly during dose escalation.

How long to stay: At least 4 weeks. Many patients do very well at 5mg for months. If you are losing 1 to 2 lbs per week consistently and tolerating the medication, there is no urgency to increase. Some people stay at 5mg for 3 to 6 months before moving up.

7.5mg: The Middle Ground (Weeks 9 to 12+)

This is often where patients feel the strongest shift in their relationship with food. The appetite suppression at 7.5mg is usually quite pronounced.

What I experienced: At 7.5mg, food noise went almost completely silent. I could look at foods I used to crave (pizza, chips, anything carb-heavy) and feel genuine indifference. Weight loss accelerated to about 2 lbs per week. The first few days after my injection each week were my lowest-appetite days, with hunger gradually returning by day 5 or 6 before the next dose.

What the data shows: The SURMOUNT-1 trial did not test 7.5mg as a standalone dose group. It was a step in the titration toward 10mg and 15mg. Clinically, this dose falls between the 5mg and 10mg efficacy levels, and many providers use it as a longer stopping point for patients who respond well.

Common side effects: Similar profile to 5mg but may be slightly more intense during the first week of the increase. Nausea, reduced appetite, and occasional acid reflux or heartburn. Some patients report sulfur burps at this dose, which are unpleasant.

How long to stay: 4 weeks minimum. If your weight loss is strong and consistent at 7.5mg, talk to your provider about staying here rather than automatically increasing. The goal is the lowest effective dose, not the highest tolerable one.

Ready to start Mounjaro? Compare providers and pricing.

Browse Provider Directory →

10mg: Higher Efficacy, More Side Effects (Weeks 13 to 16+)

The 10mg dose was a separate study arm in SURMOUNT-1, and the results were strong. Patients in this group lost an average of 19.5% of body weight over 72 weeks.

What I experienced: The increase from 7.5mg to 10mg brought back nausea that I had not felt since my first week at 5mg. Days 1 through 3 after injection were rough. I relied on small, bland meals and ginger tea to get through the initial adjustment. By week 2 at this dose, the nausea settled. Weight loss stayed around 1.5 to 2 lbs per week.

What the data shows: 10mg is where the dose-response curve starts to flatten. The jump from 5mg (15% weight loss) to 10mg (19.5%) is meaningful but not as dramatic as going from nothing to 5mg. For some patients, the additional side effects at 10mg do not justify the incremental benefit over 7.5mg.

Common side effects: In the Zepbound label’s pooled trial data, nausea was reported by 29% of patients on 10mg, the highest of the three maintenance doses, and diarrhea by 21%. GI issues tend to show up around dose increases, then improve. Injection site reactions (8%), fatigue (6%), and hair loss (4%) were also reported at 10mg. Our side effects guide covers management strategies in detail.

How long to stay: 4 weeks minimum, but some providers prefer to stay at 10mg longer to see its full effect before considering another increase. The difference between 10mg and higher doses is smaller than the difference between lower doses.

12.5mg: Approaching Maximum (Weeks 17 to 20+)

Like 7.5mg, the 12.5mg dose was not a standalone study arm in SURMOUNT-1. It is a titration step between 10mg and 15mg.

What I experienced: The transition to 12.5mg was smoother than the jump to 10mg. My body seemed more adapted to tirzepatide by this point. Appetite suppression was very strong. Some days I had to remind myself to eat dinner. Weight loss continued but at a slightly slower rate (about 1 to 1.5 lbs per week), partly because I had less weight left to lose.

What the data shows: Clinical experience suggests 12.5mg provides additional benefit for patients who have plateaued at 10mg. The side effect profile is similar to 10mg for most people, though a subset of patients experience more pronounced GI symptoms at each increase. If you are still losing weight consistently at 10mg, there may be no reason to increase.

Common side effects: Same general profile as 10mg. The patients most affected by side effects at this dose tend to be those who were already sensitive at lower levels. New side effects at this stage are uncommon. Existing ones may intensify briefly.

How long to stay: Same 4-week minimum. Your provider should assess whether the additional appetite suppression is translating into meaningful weight loss beyond what you achieved at 10mg.

15mg: Maximum Dose (Weeks 21+)

The highest FDA-approved dose of Mounjaro. In SURMOUNT-1, patients on 15mg lost an average of 20.9% of body weight over 72 weeks. That is roughly 48 lbs for the average participant, who started at about 231 lbs.

What the data shows: The difference between 10mg (19.5%) and 15mg (20.9%) was only 1.4 percentage points in SURMOUNT-1. Not all patients need this dose to reach their goals. 57% of patients on 15mg lost 20% or more of their weight, compared with 50% on 10mg, which suggests smaller added returns at the top of the dose range for many people.

Common side effects: In the Zepbound label’s pooled data, nausea affected 28% of patients on 15mg and diarrhea 23%, the highest diarrhea rate of the three doses. Vomiting hit 13%. In SURMOUNT-1, side effects led 6.2% of the 15mg group to stop treatment, versus 2.6% on placebo.

How long to stay: This is typically the maintenance dose for patients who need maximum efficacy. Once you reach your goal weight, your provider may discuss staying at 15mg or reducing to a lower maintenance dose. If you do not have diabetes, Zepbound is the obesity-labeled version of tirzepatide.

Dose-by-Dose Comparison Table

Dose	Minimum Duration	Avg Weight Loss (SURMOUNT-1)	Common Side Effects	Notes
2.5mg	4 weeks	Not tested as a treatment dose	Mild nausea, constipation	Starting dose only, not a maintenance dose
5mg	4 weeks	15.0% over 72 weeks	Nausea (25%), GI issues	First labeled maintenance dose
7.5mg	4 weeks	Between 5mg and 10mg	Similar to 5mg, sulfur burps	Good stopping point for many
10mg	4 weeks	19.5% over 72 weeks	Nausea (29%), diarrhea (21%)	Dose-response curve flattens here
12.5mg	4 weeks	Between 10mg and 15mg	Similar to 10mg	Titration step, not studied alone
15mg	Ongoing (max dose)	20.9% over 72 weeks	Nausea (28%), diarrhea (23%)	57% of patients lost 20%+

When to Stay at Your Current Dose

Not everyone needs to reach 15mg. Here are signs you should talk to your provider about staying at your current dose rather than increasing:

You are losing weight steadily. If it is working, there may be no reason to push higher. More medication does not always mean more weight loss. The SURMOUNT-1 data shows diminishing returns at higher doses.

Your side effects are manageable but noticeable. If you are dealing with mild nausea or GI symptoms at your current dose, increasing will likely make them worse for at least a few weeks. Let your body fully adjust before considering more.

You are within 10 to 15 lbs of your goal weight. At this point, the remaining weight loss will be slower regardless of dose. Increasing may not meaningfully speed things up, and the side effects may not be worth it.

Signs You Should NOT Increase

Talk to your provider immediately and do not increase your dose if you experience any of these:

Severe nausea or vomiting that lasts more than a week at your current dose
Very rapid weight loss sustained over multiple weeks (the label links gallbladder problems to weight loss)
Inability to eat regular meals or keep fluids down
Significant hair thinning or other signs of nutritional deficiency
Severe constipation that does not respond to increased fiber and hydration
Pancreatitis symptoms (severe upper abdominal pain radiating to the back)

Losing weight too fast is a real risk on GLP-1 medications. The muscle loss problem gets worse with aggressive calorie restriction, and your body needs adequate nutrition to function. If you are barely eating, a higher dose is not the answer.

What “Therapeutic Dose” Means

You will hear providers use the term “therapeutic dose” when discussing Mounjaro titration. This refers to the dose level where the medication starts producing clinically meaningful weight loss.

For tirzepatide, the therapeutic range begins at 5mg. The Zepbound label says the 2.5mg dose “is for treatment initiation and is not approved as a maintenance dosage.” It exists to reduce GI side effects during the start of treatment.

This matters because some patients get discouraged during the first month when weight loss is slow at 2.5mg. That is expected. The medication has not reached its working level yet. Once you move to 5mg, the actual treatment begins.

The effective therapeutic range for most patients falls between 5mg and 15mg. Where you land within that range depends on your individual response, your starting weight, your goals, and your tolerance for side effects. There is no single “right” dose. The right dose is the one that produces steady weight loss you can sustain without debilitating side effects.

Tips for Smoother Dose Transitions

Based on my experience and what I have seen others report, here are practical strategies for managing each dose increase:

Eat smaller, more frequent meals. Your stomach empties slower on Mounjaro. Large meals are more likely to cause nausea after a dose increase. Five small meals works better than three normal ones during the adjustment period.

Time your injection strategically. I take my injection on Friday evenings so the worst of any nausea hits on the weekend when I can rest. Many patients use a similar approach.

Stay hydrated. GI side effects like nausea and constipation get worse with dehydration. Drink enough that your urine stays pale, especially in the first week at a new dose. If you have kidney or heart problems or a fluid limit from your doctor, follow their number instead of a generic target.

Avoid fatty and fried foods for the first few days after a dose increase. These are the most common nausea triggers on tirzepatide.

Track your response. Keep a simple log of your weight, appetite level, and any side effects for the first 2 weeks at each new dose. This gives you and your provider real data to make decisions about further increases.

Safety Points From the Label

These apply at every dose. Read the full Zepbound prescribing information and follow your prescriber.

Thyroid tumor warning. Tirzepatide carries a boxed warning because it caused thyroid C-cell tumors in rats. It is unknown whether it does in people. Do not use it if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2.
Pancreatitis. Severe upper stomach pain that may spread to the back needs prompt care. The label says to stop the drug if pancreatitis is suspected.
Dehydration and kidneys. Vomiting and diarrhea can lead to dehydration, which can affect kidney function, especially around dose increases.
Birth control pills. The label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.
Pregnancy. The label says to stop Zepbound when a pregnancy is recognized.

FAQ

How often can I increase my Mounjaro dose?

The minimum time between dose increases is 4 weeks per the FDA-approved prescribing information. Your provider may recommend staying at a dose longer if you are losing weight consistently or experiencing side effects. There is no maximum time at any dose level. Some patients stay at 5mg or 7.5mg for months before moving up, or stay there permanently.

What if I feel nothing at my current Mounjaro dose?

If you are not experiencing appetite suppression or weight loss at a given dose for more than 4 weeks, talk to your provider about increasing. Some patients are “non-responders” at lower doses but respond well at higher levels. This is not unusual. The titration schedule exists specifically to find the dose that works for you.

Can I go back to a lower Mounjaro dose if I increase?

Yes. If you increase to a higher dose and find the side effects unacceptable, your provider can move you back down. This is a normal part of finding the right dose. The medication continues working at lower doses, just with potentially less appetite suppression. Do not switch doses on your own.

What happens when I reach 15mg and still have weight to lose?

If you are on the maximum 15mg dose and your weight loss has stalled, your provider will typically assess whether the medication is still working or if other factors (diet, activity level, metabolic adaptation) need attention. 15mg is the maximum dose on the FDA label for Mounjaro and Zepbound. There is no approved dose above it, so do not go higher, compounded or otherwise. The next step is usually a closer look at diet, protein, strength training, and sleep, or a conversation about a different medication. Our Mounjaro plateau guide covers strategies for breaking through weight loss stalls.

Is the titration schedule the same for Mounjaro and Zepbound?

Mostly. Zepbound is the same active ingredient (tirzepatide) as Mounjaro, with an FDA-approved weight indication rather than a diabetes indication. Both labels start at 2.5mg, go up in 2.5mg steps after at least 4 weeks, and stop at 15mg in adults. The Zepbound label names 5mg, 10mg, or 15mg as maintenance doses for weight. The products are sold and covered separately. Our cheapest GLP-1 guide compares pricing options.

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the Zepbound and Mounjaro prescribing information and the SURMOUNT-1 trial publication on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.